Nanobiotix S.A. ADR (NBTX)
NASDAQ: NBTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NBTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.35B
- EPS (TTM)
- -$1.27
- Dividend yield
- None
- 52-week range
- 19.14 – 57.14
- Day range
- 26.12 – 28.15
- Volume / Avg
- 125.28K / 148.94K
- Beta
- —
- Shares outstanding
- 50.95M
52-week range
NBTX stock today
Nanobiotix S.A. (NBTX) closed at $26.50 on Nov 20, down 2.98% (-$0.815), versus the S&P 500's 3.70% decline. At this level, NBTX sits near the bottom of its 52-week range of $19.14 to $57.14: 53.6% below the high, set on May 14, 2026 and 38.5% above the low. NBTX is up 14.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 26.6%.
Nanobiotix S.A. has posted a net loss over the last twelve months (EPS of -$1.27), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Nanobiotix S.A.
Company profileNanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Laurent Levy Ph.D.
- Headquarters
- Paris
- Employees
- 98
- IPO year
- 2020
- Website
- nanobiotix.com
Analyst forecast
ForecastConsensus (5 analysts)
none
Avg. price target
$53.28+101.06%
- Strong buy 0
- Buy 4
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
NBTX news
All NBTX news- Voting Rights and Shares Capital of the CompanyGlobeNewswireNANO, NBTX
- Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital socialGlobeNewswireNANO, NBTX
- Nanobiotix to Participate in Investor Conferences in NovemberGlobeNewswireNANO, NBTX
- NANOBIOTIX PARTICIPERA À PLUSIEURS CONFÉRENCES INVESTISSEURS EN NOVEMBREGlobeNewswireNANO, NBTX
- NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous MelanomaGlobeNewswireNANO, NBTX
- NANOBIOTIX annonce les résultats complets de l’étude de Phase 1 évaluant JNJ-1900 (NBTXR3) en combinaison avec des inhibiteurs de points de contrôle immunitaires chez des patients atteints de mélanome cutané résistant aux anti-PD-1, en traitement de deuxième ligne ou plusGlobeNewswireNANO, NBTX
- Voting Rights and Shares Capital of the CompanyGlobeNewswire
- Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital socialGlobeNewswire
Nanobiotix S.A. peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PAHCPhibro Animal Health Corporation Class A | 33.29 | -2.32% | $1.35B | vs NBTX |
| URGNUroGen Pharma Ltd. | 27.65 | -12.86% | $1.36B | vs NBTX |
| QUREuniQure N.V. | 19.35 | -4.35% | $1.36B | vs NBTX |
| NUVBNuvation Bio Inc. Class A | 3.80 | -0.26% | $1.34B | vs NBTX |
| RAPPRapport Therapeutics Inc. | 23.16 | -1.82% | $1.37B | vs NBTX |
| ANABAnaptysBio Inc. | 46.63 | -1.62% | $1.39B | vs NBTX |
| TYRATyra Biosciences Inc. | 20.12 | +1.98% | $1.39B | vs NBTX |
| INVAInnoviva Inc. | 18.41 | 0.00% | $1.31B | vs NBTX |
Indexes, lists and sector
Nanobiotix S.A. stock FAQ
What is Nanobiotix S.A.'s stock price today?
NBTX last traded at $26.50 as of Nov 20, 4:00 PM EST, down 2.98% on the day. Prices are delayed at least 15 minutes.
Who is Nanobiotix S.A.'s CEO?
Dr. Laurent Levy Ph.D. is the chief executive officer of Nanobiotix S.A. ADR, which has about 98 employees.
What is the NBTX 52-week high?
The 52-week high for NBTX is $57.14 and the 52-week low is $19.14. The stock is currently 53.6% below its high.